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Session Content
• 1.  Recommendations for commonly used 
medications in CKD
• Basic principles /patient safety of medication prescribing in CKD
• Is it ok to continue metformin in CKD?
• Should I continue or stop ACE inhibitors in patients with CKD?
• What is the story with PPI and CKD?
• 2. CKD screening and referral
• Recommendations for screening in high risk populations
• Nephrology referral:   What to do with a creatinine elevation?
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Vassalotti et al, Practical Approach to 
Detection and Management of Chronic Kidney 
Disease for the Primary Care Physician.  
AmJMed (2016) 129, 153-162.  
 
 Building a Practical Approach to 
Detection and Management of CKD
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CKD Patient Safety Issues
• Diagnostic tests
• Iodinated contrast media: AKI
• Gadolinium-based contrast: NSF
• Sodium Phosphate bowel preparations: AKI, CKD 
• Fluid management
• Hypotension/Hypertension
• Diuretics
• Concomitant heart failure management
• Pharmacology
• Drug dosing and frequency
NSF = nephrogenic systemic fibrosis.
Fink JC, Brown J, Hsu, VD, et al. Am J Kidney Dis 2009;53:681-668..
 
 
 
Metformin and Renal Impairment:  T or F?
• 1. Evaluate eGFR prior to treatment with metformin and 
annually thereafter (base assessment on eGFR and NOT 
serum creatinine)
• More frequent checks in those at risk for renal impairment
• 2. Contraindicated if eGFR < 30 ml/min
• 3. Not recommended to start if eGFR 30-45 ml/min
• 4. In those on metformin, assess risk/benefit of continuing if 
eGFR falls < 45 ml/min
• 5. Do not administer for 48 hrs after iodinated contrast 
imaging procedure in patients with eGFR 30-60 ml/min or 
h/o liver disease, alcoholism or heart failure or in 
those receiving intra-arterial contrast; restart if eGFR stable.
(FDA  April 2016)
April 2016
 
 
 Slowing CKD Progression: ACE I or ARB
• Benefits clearly demonstrated in proteinuria patients with CKD
• Risk/benefit should be carefully assessed in the elderly and 
medically fragile
• Avoid ACE I and ARB in combination1,2
o Risk of adverse events (impaired kidney function, hyperkalemia)
• Check labs 1-2 weeks after initiation: If less than 25% SCr increase, 
continue and monitor
o If more than 25% SCr increase, stop ACE I and evaluate for RAS
• Continue until contraindication arises, no absolute eGFR cutoff
• Better proteinuria suppression with low Na diet and diuretics
• Avoid volume depletion
1) Kunz R, et al. Ann Intern Med. 2008;148:30-48.
2) Mann J, et al. ONTARGET study. Lancet. 2008;372:547-553.
3) James P, et al. JAMA. 2014: 311 (5): 507-520.  
 
 
PPIs in the news
 
 
 
PPI :  association with CKD
• PPIs users (compared to users of H2 blockers or   
non-users) have increased risk of 
• AKI (including AIN)
• CKD development 
• CKD progression to ESRD
PPI associated kidney disease association is not causality
Association HR
eGFR < 60 1.19 (95% CI 1.15-1.24)
Incident CKD 1.26 (95% CI 1.20-1.33)
eGFR decline >30% 1.22 (95% CI 1.16-1.28)
ESRD or >50% ↓ eGFR 1.30 (95% CI 1.15-1.48)
1. Xie et al.  Kidney Int 2017; 1-13
2. Lazarus et al, JAMA 2016; 176(2): 238-246.
3. Xie et al, JASN 2016; 27: 3153-3163.  
 
 PPI:  Indigestion for Nephrologists
• Twice daily dosing of PPI associated with 
higher risk of CKD and AKI
• Higher risk with higher cumulative exposure but risk present 
even at > 30 days.
• >50% of patients with AIN developed CKD, despite 
discontinuation of the drug
• Reflection on practical strategy:
• Discuss PPI use with my patients and encourage alternative when possible if 
no clear indication for the medication exists
• Wean down and then off medication
• Discuss concomitant strategies:  avoiding known food triggers; using H2 
blockers instead
 
 
 
Common Medications Requiring 
Dose Reduction in CKD
• Antimicrobials
• Trimethoprim/Sulfamethoxazole
• SS tablets and adjust frequency!
• Fluoroquinolones
• Adjust dose and frequency
• Antifungals
• Fluconazole
• CKD 4 and 5- 50%
• Antivirals
• Acyclovir
• CKD stage 4, 5- adjust frequency!
• GI cocktails
• Avoid Mg containing agents
• Avoid Fleets (P containing)
• Antihypertensive medications
• Atenolol
CKD 4- 50%
CKD 5- 25%
• Bisoprolol
CKD 4- 75%
CKD 5- 50%
• Analgesics
• Minimize NSAIDs
• Gout medications
o Colchicine
o Allopurinol
o NO INDOMETHACIN
• Neuropathy medications
o Gabapentin
• CKD 4- Max dose 200-700mg qd
• CKD 5- Max dose 300mg qd or qodMunar et at.  AFP 2007; 75 (10): 1487-1496  
 
 
Session Content
• 1.  Recommendations for commonly used 
medications in CKD
• Guidelines/basic principles of medication prescribing in CKD
• Is it ok to continue metformin in CKD?
• Should I continue or stop ACE inhibitors in patients with CKD?
• What is the story with PPI and CKD?
• 2. CKD screening and referral
• Recommendations for screening in DM and HTN (high risk 
populations)
• Nephrology referral:   What to do with a creatinine elevation?
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 Gaps in CKD Diagnosis
Szczech, Lynda A, et al. "Primary Care Detection of Chronic Kidney Disease in Adults with Type-
2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type-2 Diabetes 
and Chronic Kidney Disease)." PLOS One - In press (2014).
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Improved Diagnosis
Studies demonstrate that clinician behavior changes when 
CKD diagnosis improves. Significant improvements 
realized in:1-3
• Increased urinary albumin testing
• Increased appropriate use of ACE I or ARB
• Avoidance of NSAIDs prescribing among patients with low eGFR
• Appropriate nephrology consultation
1. Wei L, et al. Kidney Int. 2013;84:174-178.
2. Chan M, et al. Am J Med. 2007:120;1063-1070.
3. Fink J, et al. Am J Kidney Dis. 2009,53:681-668.NKF.
 
 
 
Screening for CKD
High Risk Patients
• HTN Certain ethnicities Autoimmune disease
• DM FH of CKD Reduced renal mass (solitary kidney)
• CV disease Prior AKI Nephrotoxin exposure
• Obesity Obstruction
eGFR microalbuminuria or proteinuria
 
 
 Screening Tools: eGFR
• Considered the best overall index of kidney function. 
• Normal GFR varies according to age, sex, and body 
size, and declines with age. 
• Equations can be misleading with “normal” kidney 
function, obesity, advanced age
MDRD equation:
1. Determinant of body size is pre-packaged into this equation
2. Developed in patients with GFR < 60
Summary of the MDRD Study and CKD-EPI Estimating Equations: 
https://www.kidney.org/sites/default/files/docs/mdrd-study-and-ckd-epi-gfr-estimating-equations-summary-ta.pdf  
 
 
eGFR tools: case 1
• 25 yo healthy male, exercises, BMI satisfactory but 
creatinine was elevated and eGFR by MDRD was 67
mdrd.com
 
 
 
 
 
 Age related declines in eGFR
• Should not be considered a disease
• “Normal” may be eGFR 60-89 ml/min/1.73 m2
• May not need referral to nephrology if
• No proteinuria
• No hematuria
• No structural lesion
• Stable serum creatinine
 
 
 
Microalbuminuria and Proteinuria
Category Spot (mg/g creatinine)
Normoalbuminuria < 30
Microalbuminuria 30-300
Macroalbuminuria > 300
 
 
 
Screening for CKD
High Risk Patients
• HTN Autoimmune disease Reduced renal mass (solitary kidney)
• DM Obstruction Nephrotoxin exposure
• FH of CKD Prior AKI Certain ethnicities
eGFR microalbuminuria or proteinuria
If eGFR is normal and no 
microalbuminuria, repeat kidney 
check tests in 1-2 years (annually 
for DM and HTN)
If eGFR is abnormal and 
+proteinuria proceed to 
heat map
 
 
  
 
 
When to refer to nephrology?
• AKI or unexplained elevation in serum creatinine
• CKD with eGFR < 30
• Evidence of intrinsic renal disease
• Microscopic hematuria with rbc casts and/or proteinuria
• Persistent proteinuria
• Hypertension, refractory to treatment 
• Electrolyte abnormalities (K , Na)
• Hereditary kidney disease (ADPKD)
• STONE CLINIC REFERRAL:  Recurrent or extensive nephrolithiasis
 
 
 
Key Points on Medications, Patient Safety, 
Screening and Referral in CKD
• Use eGFR when prescribing medications
• creatinine can be misleading in elderly, reduced muscle mass….
• Any med with >30% renal clearance probably need dose adjustment for 
CKD
• Avoid NSAIDs
• Avoid gadolinium (MRI) for eGFR <30
• No Dual RAAS blockade (JNC 8)
• Keep up with the news and patient safety issues
• In high risk patients check urine protein and eGFR
• Use the heat-map as a guide to referral to nephrology and monitoring
 
 
 
 
 10 commandments of CKD 
management by primary care providers
• 10.   Thou shalt evaluate and treat cardiovascular risk 
and comorbidities
• 9. Thou shalt treat BP to target ranges 
• 8. Thou shalt use mathematical formulas to estimate 
eGFR
• 7. Though shalt screen for microalbuminuria/proteinuria 
in high risk patients
• 6. Thou shalt pay attention to patient safety issues 
related to CKD stages 3 onward, including radiocontrast 
for diagnostic imaging.  
• 5. Thou shalt dose medications appropriately
• 4. Thou shalt monitor progression according to the “heat 
map”
• 3. Thou shalt embrace ACE inhibitors (until the bitter end 
unless otherwise contraindicated)
• 2. Thou shalt avoid NSAIDs
• 1. Thou shalt make appropriate nephrology referrals
 
 
 
CKD in the Clinic
A joint venture between 
nephrology and primary care
Thank you!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
